Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

35.62 -0.52 (-1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right.
With two huge catalysts drawing near, its stock could go even higher. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
3 Monster Stocks in the Making to Buy Right Now
They're not monsters now -- but just give them some time. 
Via The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
CRISPR stock has climbed more than 40% so far this year. 
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 10 Years?
The biotech is part of a revolution in gene-editing therapies. 
Via The Motley Fool
What 17 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Can This Gene-Editing Stock Deliver 10X Returns?
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
There's more than one reason to sell a stock while buying another. 
Via The Motley Fool
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
This company has several catalysts for growth coming up, with more on the way. 
Via The Motley Fool
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
3 Cathie Wood Investments That Could Deliver Superior Returns
These three stocks fit Wood's profile for big-time growth. 
Via The Motley Fool
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?
All eyes are on CRISPR Therapeutics' gene editing technology. 
Via The Motley Fool
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
2 Biotech Stocks That Could Help Make You a Fortune
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent... 
Via Benzinga
Carvana (CVNA) Stock Continues to Move on Improved Outlook
Carvana (CVNA) stock is still a hot topic among traders on Friday after the used-car retailer updated its outlook yesterday. 
Via InvestorPlace
TGT Stock Alert: Have Target’s Sales Numbers Peaked?
Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer. 
Via InvestorPlace
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
Wall Street Loves These 3 Growth Stocks -- Should You?
Analysts think all three of these stocks could soar. 
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.